CommercialCoverageLow impact
Blue Cross and Blue Shield of Alabama’s Collaborative Support of CivicaScript® Helps Save Patients Nearly $1,000 per Year on a Generic Drug
Blue Cross Blue Shield of Alabama·AL · Oncology, Pharmacy·Pharmacy
We identified it
Jun 4, 2025
Summary
Blue Cross and Blue Shield of Alabama is partnering with CivicaScript® to offer a lower-cost generic alternative for abiraterone acetate (prostate cancer treatment), reducing patient out-of-pocket costs from $126/month to $45/month (64% savings). This is an informational announcement about a pharmacy benefit expansion with no direct billing code or workflow changes required for the practice.
Action Required
No immediate action required. This is a patient benefit announcement, not a billing policy change. Billing teams should be aware that BCBS Alabama members with prostate cancer may now have access to lower-cost abiraterone acetate through CivicaScript. If patients inquire about prescription costs, direct them to their plan documents or BCBS customer service. Monitor for additional CivicaScript product launches expected by fall 2025, which may warrant future review.